- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.01. | Reportable, Inc.: Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) | 584 | Newsfile | Dallas, Texas--(Newsfile Corp. - January 9, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners initiates their coverage on NeOnc Technologies Holdings, Inc. (NASDAQ:... ► Artikel lesen | |
| 21.12.25 | New to The Street Broadcasts Nationwide Tonight on Bloomberg Television Featuring NeOnc, Metaterra Holdings Inc., CISO Global, and NRx Pharmaceuticals | 1.183 | ACCESS Newswire | Commercial sponsors are, Sustainable Green Team (SGTM) , Synergy CHC ($SNYR), DataVault AI ($DVLT),ACURX ($ACXP) ,($PETV) and Aeries Technology ($AERT) NEW YORK CITY, NEW YORK / ACCESS Newswire / December... ► Artikel lesen | |
| 17.12.25 | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.12.25 | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Reports Updated Clinical Results | 170 | GlobeNewswire (Europe) | CALABASAS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| 13.12.25 | NEONC TECHNOLOGIES HOLDINGS, INC. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 05.12.25 | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 01.12.25 | Ultraschall steigert Wirksamkeit der Hirntumor-Therapie NEO100 von NeOnc | 1 | Investing.com Deutsch | ||
| NEONC TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 01.12.25 | NeOnc's NEO100 shows enhanced brain tumor treatment with ultrasound | 1 | Investing.com | ||
| 01.12.25 | NeOnc Technologies Holdings, Inc.: NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors | 1 | GlobeNewswire (USA) | ||
| 14.11.25 | NeOnc Technologies Holdings GAAP EPS of -$0.45 | 1 | Seeking Alpha | ||
| 14.11.25 | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update | 287 | GlobeNewswire (Europe) | CALABASAS, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies... ► Artikel lesen | |
| 14.11.25 | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High-Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026) | 219 | GlobeNewswire (Europe) | CALABASAS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering... ► Artikel lesen | |
| 06.11.25 | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 04.11.25 | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth | 1 | GlobeNewswire (USA) | ||
| 30.10.25 | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.10.25 | NeOnc Technologies Holdings, Inc.: His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment | 238 | GlobeNewswire (Europe) | CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 28, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical... ► Artikel lesen | |
| 09.10.25 | NeOnc Technologies schließt Forschungsabkommen in den VAE und erweitert Vorstand | 1 | Investing.com Deutsch | ||
| 09.10.25 | NeOnc Technologies signs UAE research agreement, expands board | 2 | Investing.com |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,335 | -0,85 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen auf "Buy" mit einem Kursziel von 46 Euro belassen. 2025 sei ein weiteres durchwachsenes Jahr für den Medizintechnik-/Life-Sciences-Sektor... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,400 | 0,00 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 37,650 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 69,98 | 0,00 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| IMMUNOVANT | 26,450 | +1,50 % | Immunovant Inc.: Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 | ||
| ALUMIS | 26,840 | 0,00 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 11,160 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,880 | +1,02 % | Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? | ||
| STRUCTURE THERAPEUTICS | 87,15 | -2,13 % | Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It | ||
| IMMUNOME | 25,070 | 0,00 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| ERASCA | 10,310 | +1,78 % | Erasca, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 72,56 | +0,14 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| BIONTECH | 97,75 | +0,10 % | BERENBERG stuft Biontech auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Biontech auf "Buy" mit einem Kursziel von 155 US-Dollar belassen. 2025 sei ein weiteres durchwachsenes Jahr für den Medizintechnik-/Life-Sciences-Sektor... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,68 | +1,54 % | Piper Sandler raises Praxis Precision Medicines stock price target to $1,200 | ||
| RECURSION PHARMACEUTICALS | 4,320 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen |
NEONC TECHNOLOGIES HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 8,750 Euro und damit -10,35 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEONC TECHNOLOGIES HOLDINGS INC finden Sie auf Wallstreet Online.